H. Rex, M.D.
of Infectious Diseases, Department of Internal Medicine,
for the Study of Emerging and Reemerging Pathogens,
of Texas Medical School, Houston, Texas
AstraZeneca, Alderley House, Alderley
Macclesfield Cheshire, SK10 4TF,
Dr. Rex received his M.D. from Baylor College of Medicine. He performed
his residency at the Stanford University Hospitals & Clinics and fellowship at
the National Institute of Allergy and Infectious Diseases
Dr. Rex's work is focused in three areas. First, he participated in a variety of clinical trials that
investigate the utility of new antifungal agents in human infection.
His work in this area has focused primarily on invasive fungal infections of the critically-ill
Dr. Rex's laboratory is involved in a variety of studies on the technical aspects of
in vitro susceptibility testing. He is a member of the National Committee
for Clinical Laboratory Standards' Antifungal Susceptibility Testing Subcommittee.
Through the work done in his laboratory with this committee, he has had the opportunity to
participate in the development of the M27 and M38 documents on susceptibility testing of yeasts and moulds,
Dr. Rex's laboratory uses animal models of invasive fungal infections to investigate better ways to treat these infections in humans.
He and collogues investigate both new drugs and new ways to better use old drugs. These studies are often directly tied to better understanding of ways to use in vitro susceptibility testing to predict response to